
Anne Marie Sabrina Wehbe
Examiner (ID: 18312)
| Most Active Art Unit | 1633 |
| Art Unit(s) | 1632, 1633, 1634 |
| Total Applications | 1342 |
| Issued Applications | 603 |
| Pending Applications | 239 |
| Abandoned Applications | 542 |
Applications
| Application number | Title of the application | Filing Date | Status |
|---|---|---|---|
Array
(
[id] => 16266465
[patent_doc_number] => 20200267952
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2020-08-27
[patent_title] => TRANSGENIC NON-HUMAN VERTEBRATE FOR THE IN VIVO PRODUCTION OF DUAL SPECIFICITY IMMUNOGLOBULINS OR HYPERMUTATED HEAVY CHAIN ONLY IMMUNOGLOBULINS
[patent_app_type] => utility
[patent_app_number] => 16/869416
[patent_app_country] => US
[patent_app_date] => 2020-05-07
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 52575
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -17
[patent_words_short_claim] => 123
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16869416
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/869416 | TRANSGENIC NON-HUMAN VERTEBRATE FOR THE IN VIVO PRODUCTION OF DUAL SPECIFICITY IMMUNOGLOBULINS OR HYPERMUTATED HEAVY CHAIN ONLY IMMUNOGLOBULINS | May 6, 2020 | Pending |
Array
(
[id] => 17670963
[patent_doc_number] => 20220184130
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-06-16
[patent_title] => ARTIFICIAL SIGNALLING MOLECULE
[patent_app_type] => utility
[patent_app_number] => 17/605180
[patent_app_country] => US
[patent_app_date] => 2020-04-30
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 5993
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -25
[patent_words_short_claim] => 44
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17605180
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/605180 | ARTIFICIAL SIGNALLING MOLECULE | Apr 29, 2020 | Pending |
Array
(
[id] => 17670963
[patent_doc_number] => 20220184130
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-06-16
[patent_title] => ARTIFICIAL SIGNALLING MOLECULE
[patent_app_type] => utility
[patent_app_number] => 17/605180
[patent_app_country] => US
[patent_app_date] => 2020-04-30
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 5993
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -25
[patent_words_short_claim] => 44
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17605180
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/605180 | ARTIFICIAL SIGNALLING MOLECULE | Apr 29, 2020 | Pending |
Array
(
[id] => 16510818
[patent_doc_number] => 20200390074
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2020-12-17
[patent_title] => Non-Mammalian RAS Transgenic Animal Model
[patent_app_type] => utility
[patent_app_number] => 16/854118
[patent_app_country] => US
[patent_app_date] => 2020-04-21
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 10642
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -14
[patent_words_short_claim] => 12
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16854118
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/854118 | Non-Mammalian RAS Transgenic Animal Model | Apr 20, 2020 | Abandoned |
Array
(
[id] => 16283769
[patent_doc_number] => 20200277371
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2020-09-03
[patent_title] => Restricted Immunoglobulin Heavy Chain Mice
[patent_app_type] => utility
[patent_app_number] => 16/851902
[patent_app_country] => US
[patent_app_date] => 2020-04-17
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 28427
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -21
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16851902
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/851902 | Restricted Immunoglobulin Heavy Chain Mice | Apr 16, 2020 | Abandoned |
Array
(
[id] => 16204835
[patent_doc_number] => 20200237825
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2020-07-30
[patent_title] => ENGINEERING AND DELIVERY OF THERAPEUTIC COMPOSITIONS OF FRESHLY ISOLATED CELLS
[patent_app_type] => utility
[patent_app_number] => 16/849954
[patent_app_country] => US
[patent_app_date] => 2020-04-15
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 14043
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -42
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16849954
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/849954 | ENGINEERING AND DELIVERY OF THERAPEUTIC COMPOSITIONS OF FRESHLY ISOLATED CELLS | Apr 14, 2020 | Abandoned |
Array
(
[id] => 16295452
[patent_doc_number] => 20200281175
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2020-09-10
[patent_title] => HUMANIZED NON-HUMAN ANIMALS WITH RESTRICTED IMMUNOGLOBULIN HEAVY CHAIN LOCI
[patent_app_type] => utility
[patent_app_number] => 16/849782
[patent_app_country] => US
[patent_app_date] => 2020-04-15
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 49514
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -45
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16849782
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/849782 | Humanized non-human animals with restricted immunoglobulin heavy chain loci | Apr 14, 2020 | Issued |
Array
(
[id] => 16388743
[patent_doc_number] => 20200329684
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2020-10-22
[patent_title] => METHOD FOR OBTAINING RETINAL DEGENERATION (rd) MODEL MOUSE HAVING LOW RISK OF CAUSING RETINAL DETACHMENT
[patent_app_type] => utility
[patent_app_number] => 16/846718
[patent_app_country] => US
[patent_app_date] => 2020-04-13
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 3153
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -6
[patent_words_short_claim] => 64
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16846718
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/846718 | METHOD FOR OBTAINING RETINAL DEGENERATION (rd) MODEL MOUSE HAVING LOW RISK OF CAUSING RETINAL DETACHMENT | Apr 12, 2020 | Abandoned |
Array
(
[id] => 20386610
[patent_doc_number] => 12486327
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2025-12-02
[patent_title] => CAR for use in the treatment of HvG disease
[patent_app_type] => utility
[patent_app_number] => 17/442759
[patent_app_country] => US
[patent_app_date] => 2020-03-30
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 8
[patent_figures_cnt] => 10
[patent_no_of_words] => 2843
[patent_no_of_claims] => 22
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 70
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17442759
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/442759 | CAR for use in the treatment of HvG disease | Mar 29, 2020 | Issued |
Array
(
[id] => 20386610
[patent_doc_number] => 12486327
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2025-12-02
[patent_title] => CAR for use in the treatment of HvG disease
[patent_app_type] => utility
[patent_app_number] => 17/442759
[patent_app_country] => US
[patent_app_date] => 2020-03-30
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 8
[patent_figures_cnt] => 10
[patent_no_of_words] => 2843
[patent_no_of_claims] => 22
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 70
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17442759
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/442759 | CAR for use in the treatment of HvG disease | Mar 29, 2020 | Issued |
Array
(
[id] => 16397273
[patent_doc_number] => 20200338131
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2020-10-29
[patent_title] => Method
[patent_app_type] => utility
[patent_app_number] => 16/827708
[patent_app_country] => US
[patent_app_date] => 2020-03-24
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 19382
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -17
[patent_words_short_claim] => 61
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16827708
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/827708 | Method | Mar 23, 2020 | Abandoned |
Array
(
[id] => 17609888
[patent_doc_number] => 20220152167
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-05-19
[patent_title] => IMMUNOGENIC FORMULATIONS FOR TREATING CANCER
[patent_app_type] => utility
[patent_app_number] => 17/436380
[patent_app_country] => US
[patent_app_date] => 2020-03-05
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 10715
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -77
[patent_words_short_claim] => 80
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17436380
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/436380 | IMMUNOGENIC FORMULATIONS FOR TREATING CANCER | Mar 4, 2020 | Pending |
Array
(
[id] => 19104692
[patent_doc_number] => 11957765
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2024-04-16
[patent_title] => Gene therapy for neurometabolic disorders
[patent_app_type] => utility
[patent_app_number] => 16/808206
[patent_app_country] => US
[patent_app_date] => 2020-03-03
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 18
[patent_figures_cnt] => 37
[patent_no_of_words] => 13659
[patent_no_of_claims] => 9
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 84
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16808206
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/808206 | Gene therapy for neurometabolic disorders | Mar 2, 2020 | Issued |
Array
(
[id] => 16072463
[patent_doc_number] => 20200190218
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2020-06-18
[patent_title] => ENHANCED PRODUCTION OF IMMUNOGLOBULINS
[patent_app_type] => utility
[patent_app_number] => 16/802978
[patent_app_country] => US
[patent_app_date] => 2020-02-27
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 12502
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -19
[patent_words_short_claim] => 82
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16802978
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/802978 | ENHANCED PRODUCTION OF IMMUNOGLOBULINS | Feb 26, 2020 | Abandoned |
Array
(
[id] => 16108501
[patent_doc_number] => 20200206273
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2020-07-02
[patent_title] => METHOD FOR CHEMOSELECTION
[patent_app_type] => utility
[patent_app_number] => 16/798108
[patent_app_country] => US
[patent_app_date] => 2020-02-21
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 10430
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -40
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16798108
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/798108 | Method for chemoselection | Feb 20, 2020 | Issued |
Array
(
[id] => 16266463
[patent_doc_number] => 20200267950
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2020-08-27
[patent_title] => RODENTS HAVING GENETICALLY MODIFIED SODIUM CHANNELS AND METHODS OF USE THEREOF
[patent_app_type] => utility
[patent_app_number] => 16/797280
[patent_app_country] => US
[patent_app_date] => 2020-02-21
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 31250
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -27
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16797280
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/797280 | Rodents having genetically modified sodium channels and methods of use thereof | Feb 20, 2020 | Issued |
Array
(
[id] => 15863043
[patent_doc_number] => 20200138925
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2020-05-07
[patent_title] => PROSTATE CANCER VACCINE
[patent_app_type] => utility
[patent_app_number] => 16/745629
[patent_app_country] => US
[patent_app_date] => 2020-01-17
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 11411
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -6
[patent_words_short_claim] => 9
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16745629
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/745629 | PROSTATE CANCER VACCINE | Jan 16, 2020 | Abandoned |
Array
(
[id] => 16188560
[patent_doc_number] => 20200229409
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2020-07-23
[patent_title] => RODENT MODEL OF MOOD DISORDERS
[patent_app_type] => utility
[patent_app_number] => 16/744493
[patent_app_country] => US
[patent_app_date] => 2020-01-16
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 19195
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -17
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16744493
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/744493 | Rodent model of mood disorders | Jan 15, 2020 | Issued |
Array
(
[id] => 16220484
[patent_doc_number] => 20200245600
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2020-08-06
[patent_title] => In Vivo Method for Generating Diversity in a Protein Scaffold
[patent_app_type] => utility
[patent_app_number] => 16/735468
[patent_app_country] => US
[patent_app_date] => 2020-01-06
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 8702
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -15
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16735468
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/735468 | In vivo method for generating diversity in a protein scaffold | Jan 5, 2020 | Issued |
Array
(
[id] => 17074901
[patent_doc_number] => 11111286
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2021-09-07
[patent_title] => T cell receptors and immune therapy using the same against PRAME positive cancers
[patent_app_type] => utility
[patent_app_number] => 16/731139
[patent_app_country] => US
[patent_app_date] => 2019-12-31
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 32
[patent_figures_cnt] => 32
[patent_no_of_words] => 21503
[patent_no_of_claims] => 20
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 319
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16731139
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/731139 | T cell receptors and immune therapy using the same against PRAME positive cancers | Dec 30, 2019 | Issued |